trending Market Intelligence /marketintelligence/en/news-insights/trending/gKmob7X_B9SKBJH90ErTow2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

BLS Pharma alleges Inovio, Genetronics' breach of contract cost it $72.9M

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


BLS Pharma alleges Inovio, Genetronics' breach of contract cost it $72.9M

BLS Pharma alleges that Inovio Pharmaceuticals Inc. and Genetronics Inc.'s breach of a supply agreement cost the company at least $72.9 million in profits.

BLS filed a complaint against the biotechnology companies last month for going back on an agreement to supply it with 25,000 units of Zetajet, a needle-free syringe developed by shareholders of BLS, who sold its rights to Inovio and Genetronics.

The rights were sold with the condition that Genetronics would execute a license and supply agreement to supply Zetajet units to BLS Pharma upon request.

BLS claims that it could not sell its testosterone replacement therapy because Inovio and Genetronics refused to supply the syringes, according to a Jan. 7 press release.

The company's therapy treats male hypogonadism, a condition in which the body has a reduced ability to produce testosterone.